PRIMARY MYELOFIBROSIS

This study tests a two-step approach for people with advanced myeloproliferative neoplasms (blood cancers). First, patients receive a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) to reduce cancer cells. Then, they undergo a donor…

This study tests whether adding the drug ruxolitinib to standard transplant care can prevent a serious side effect called graft-versus-host disease (GVHD) in older adults with myelofibrosis or related blood cancers. About 50 participants will receive ruxolitinib before, during, a…

This study is for people with myelofibrosis, a type of bone marrow cancer. It tests giving a JAK inhibitor drug before, during, and after a stem cell transplant from a half-matched donor. The goal is to reduce a serious side effect called graft-versus-host disease without raising…

This study tests whether adding iadademstat to standard ASTX727 therapy improves outcomes for people with advanced myeloproliferative neoplasms (MPNs), a group of blood cancers. About 62 adults with accelerated or blast-phase MPNs will be randomly assigned to receive ASTX727 alon…

This study tests a new automated method to select specific stem cells (CD34+) for patients with blood cancers who need a stem cell boost or second transplant. The goal is to lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the pa…

This study tests whether combining two drugs, momelotinib and luspatercept, can help people with myelofibrosis go without blood transfusions for at least 12 weeks. About 68 adults who either haven't tried or have already used certain other treatments will take part. The goal is t…

This early-stage study tests an experimental pill, AJ1-11095, in people with a bone marrow cancer called myelofibrosis. Participants must have already tried a standard JAK2 inhibitor without success. The main goals are to check the drug's safety and find the best dose for future …

This study tests whether adding navtemadlin to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis who didn't get enough benefit from ruxolitinib. About 600 adults with high- or intermediate-risk myelofibrosis will take part. The goal i…

This study is testing an experimental drug called DISC-0974 in about 150 adults with myelofibrosis or myelodysplastic syndrome (MDS) who also have anemia. The goal is to see if the drug can help patients produce enough red blood cells so they no longer need regular blood transfus…

This study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who have already been taking the drug bomedemstat and are doing well on it. The goal is to collect more information on the drug's long-term safety and how well it continues to wo…

This study tests a drug called tasquinimod, given alone or with another drug (ruxolitinib), to see if it can help control myelofibrosis—a serious bone marrow disorder. About 33 adults with primary myelofibrosis or related forms who haven't responded to other treatments will take …

This study is a registry that will follow about 200 people in Germany who have myelofibrosis (a rare bone marrow disorder) and anemia. It does not test a new treatment but instead collects information on which therapies patients receive, how their blood counts and spleen size res…

This study looks at a type of immune cell called monocytes in people with certain blood cancers (myeloproliferative neoplasms). Researchers want to see if these cells have unique features that could help diagnose the disease more accurately. About 70 adults with polycythemia vera…